Fresenius Sues InvaGen Over Generic PhosLo GelCaps

Law360, New York (September 16, 2011, 7:09 PM EDT) -- Fresenius Medical Care Holdings Inc. slapped InvaGen Pharmaceuticals Inc. with a patent infringement suit Friday in Massachusetts federal court in an effort to block it from marketing a generic version of PhosLo GelCaps.

Dialysis services provider Fresenius filed suit after InvaGen filed an abbreviated new drug application with the U.S. Food and Drug Administration to sell a generic form of PhosLo GelCaps, used in end-stage renal failure to boost calcium levels and combat high levels of phosphate in the blood, before Fresenius’ patent for the drug...
To view the full article, register now.